In addition to patents, Prolanta has received orphan designation from the US FDA for the treatment of ovarian cancer, which provides for seven years of market exclusivity. Oncolix intends to apply for orphan designation in the EU and Japan to treat ovarian cancer, both which provide for 10 years of market exclusivity.
Furthermore, under the US Affordable Care Act in the United States, biologicals such as Prolanta are granted 12 years of market exclusivity.
General Area of Claim
|Use of Anti-Prolactin Agents to Treat Cancer/Proliferative Conditions||US 7,115,556|
|Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/Neu signaling Pathway||US 8,754,031|
|Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells (Ovarian Cancer Claims)|
United Kingdom 2400979
|Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins|
US 8,304, 381
|Multimeric Ligands with Enhanced Stability|
United Kingdom 2385132
United Kingdom 1576097
|Use of Prolactin in the Prophylactic Treatment of Cancer|
United Kingdom 1579985
|Bi-Functional Cancer Treatment Agents||US 7,201,905|